HONG KONG -- PRB Pharmaceuticals and Lees Pharmaceuticals announced that they are working with government and hospital officials in Southeast Asia to provide VIRA 38 for the treatment and prevention of bird flu (H5N1). VIRA 38 is on the market in Hong Kong and the will be available in China and Taiwan soon.
VIRA 38, a composition of plant extracts, first gained notoriety during the Taiwan SARS outbreak of 2003 when it was used by the Taiwan presidential staff and doctors at Sungshan Hospital (SARS management facility) and again in the spring of 2004 when it was discovered that compounds in VIRA 38 block bird flu virus (H5N1) infections.
The World Health Organization has urged our industry to step up efforts to address the bird flu situation. To meet this challenge, we are donating VIRA 38 to medical staff and select high risk groups in bird flu-afflicted areas, said Dr. Charles Hensley, chairman and CEO of PRB Pharmaceuticals.
VIRA 38 will be used initially to protect high-risk groups such as hospital medical staff and rural farming households, said Dr. Benjamin Li, CEO of Lees Pharmaceuticals. It is of critical importance to protect the population at large. VIRA 38 is currently being used as a preventive measure by workers in live poultry markets in Hong Kong, the source of the original outbreak of bird flu in humans.
Our concern with the situation in Southeast Asia and Vietnam in particular is that as more human bird flu cases occur, the chances become greater the virus will ignite a global pandemic that could kill up to 100 million people worldwide, added Hensley. This is a deadly game of Russian Roulette.
About VIRA 38
VIRA 38, PRB Pharmaceuticals over-the-counter broad spectrum anti-viral medication is known for its effectiveness in treating and preventing influenza. VIRA 38 has recently been shown to contain compounds that inhibit the bird flu (H5N1) virus. Researchers at the Chinese University of Hong Kong have previously discovered these same compounds to be effective against a variety of pathogens including SARS CoV, the virus responsible for causing severe acute respiratory syndrome.
Source: PRB Pharmaceuticals
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.